Michael R. Green

Prevalence and Detection of Counterfeit Pharmaceuticals: A Mini Review

Paul N. Newton, Facundo M. Fernández, P. Newton, 2008 .

EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner

Romi Gupta, N. Wajapeyee, Michael R. Green, 2021, Proceedings of the National Academy of Sciences.

Group A streptococcal meningitis: case report and review of the literature.

Michael R. Green, N. Perera, L. Abulhoul, 2005, The Journal of infection.

Antimalarial drug quality: Methods to detect suspect drugs

P. Newton, F. Fernández, H. Kaur, 2010 .

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma

R. Davis, Shouhao Zhou, Xiaoyun Cheng, 2022, Blood advances.

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Naveen Garg, Xiaoping Su, M. Konopleva, 2021, Blood.

Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL

C. Flowers, D. Chihara, L. Fayad, 2021, Blood.

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Naveen Garg, Xiaoping Su, M. Konopleva, 2021, Blood.

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

M. Socinski, J. Herndon, E. Vokes, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Hospital-associated measles outbreak - Pennsylvania, March-April 2009.

James E. Levin, W. Bellini, V. Dato, 2012, MMWR. Morbidity and mortality weekly report.